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CPI Standard vs Reverse p < 0.01; Medtronic Standard vs Reverse p < 0.01; Ventritex
Standard vs Reverse p < 001
Conclusion: When defibrillation shocks are delivered through a single right
ventricular lead/defibrillator can system reverse polarity provides better de-
fibrillation efficacy regardless of the biphasic waveform used.
Ventritex
93 ± 4.3
6.7 ± 3.7
8.3 ± 35
5.2 ± 2.5
Medtronic
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In ten dogs we assessed the impact On defibrillation success of reverse po-
larity biphasic shocks, using the CPI, Medtronic and Ventritex biphasic wave-
forms delivered through a right ventricular (RV) coil/CAN system. In each ani-
mal the three biphasic waveforms were tested in random order. Similarly with
each waveform the defibrillation threshold (DFT) achieved using the standard
and reverse polarity were randomly determined. A 5 cm long coil with 426
mm2 surface area was advanced in the RV through the jugular vein and the
80 cm2 defibrillator can was placed in the subcutaneous tissue of the left su-
perior chest wall. Shocks were delivered between the RV coil as cathode and
the CAN as anode (standard polarity) and vice versa (reverse polarity). Trip-
licate defibrillation thresholds were obtained with each biphasic waveform.
DFT values are shown below:
opposing effects On defibrillation energy, so that there was nO net change in
the ED50 in heart failure.
Conclusion: The defibrillation efficacy of a biphasic waveform in a transve-
nous lead system is not changed by the development of heart failure in the
rapid paced canine model. The energy required for defibrillation was pre-
dicted by the ventricular size and wall thickness but not EF.
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We previously reported that biphasic shocks of "reversed" polarity (RP: an-
ode ~ distal coil, cathode = proximal coil) delivered through a transve-
nous/subcutaneous lead system are more effective in defibrillating the
porcine heart than those of "initial" polarity (IP: anode = proximal coil, cath-
ode = distal coil). The purpose of the study was to determine whether these
findings could be confirmed in human implants of cardioverter/defibrillators
(ICD) and a tranSvenous lead system.
We randomly assigned 18 pts who underwent ICD implantation (Medtronic
PCD "Jewel"® 13 pts, CPI Ventak P2® 4 pts, CPI Ventak PRx2® 1 pt) to IP
or RP. Two different lead systems were used (Endotak C® or Transvene®).
Defibrillation threshold (DFT) testing was performed by stepwise reduction
of defibrillation energy from 20 Joules (J) to 1.5 J or the first unsuccessful
shock. At this point, polarity was switched (IP --> RP or RP --> IP. respectively)
and DFT testing continued with switched polarity starting at the previously
unsuccessful energy level.
Results: In 7 of 18 pts who RP was better than IP; DFT differed by 10 J
in 3, by 6 J in 1, by 5 J in 2 and by 3 J in 1 pI. In 11 pts no difference was
found. Mean DFT was 9.2 ± 4.3 J with RP vs. 11.9 ± 4.8 J with IP (p < 0.01
in paired ttest). There was nO difference in shock impedance between both
polarities (lP: 49.9 ± 7.1 n vs. RP: 51.1 ± 8.1 n, p = n.s.)
Conclusions: 1) Simple reversal of electrode polarity may result in DFTs
equal or better than with IP in pts undergoing transvenous ICD implants
with biphasic shock forms. Therefore RP should be tested first during ICD
implantation. 2) The advantage of RP cannot be explained by differences in
impedance.
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Biphasic Shocks of "Reversed" Polarity are Superior
to Those of "Initial" Polarity In Defibrillation of the
Heart in Patients Undergoing Transvenous
Cardioverter/Deflbrillator Implantation
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1767-31 Reverse Polarity Biphasic Defibrillation with Three
Biphasic Waveforms Using a Unipolar Defibrillation
System
Andrea Natale, Keith Newby, Lynn Moredock, Judy Rembert, J. Marcus Wharton,
Robert Sorrentino, Ruth Ann Greenfield, Kenneth G. Morris. VA Medical
Center/Duke University. Durham, NC
CAD (n = 206) No CAD (n ~ 94)
DD ID II DD ID II
Number of patients 58 95 49 28 49 15
Age (years) 59 57 58 +++ 50 52 47
ACE Activity (nmol/min/ml) 113 96 82' + 113 104 90
3 Vessel Disease (%) 50 38 45 +++ 0 0 0
Extent (%) 53 52 54 +++ 10 11 9
> 140/90 mmHg (%) 38 43 31 + 29 26 13
ChollHDL ratio (1) 6.6 6.1 6.1 +++ 50 56 73
Apolipoprotein B(mg/dl) 154 142 149 +++ 117 129 138
Triglycerides (mg/dl) 182 155 174 + 140 150 194
Abnormal GT (%) 77 66 45' ++ 50 45 40
Overweight (%) 57 48 45 + 25 33 60
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1766-61 Angiotensin-Converting Enzyme Polymorphism in
Patients with Coronary Artery Disease and in
Controls
Bernhard R. Winkelmann, Andreas Russ, Georg Matheis, Bernhard Bohm,
Barbel Klein, Winfried Marz. J. W Goethe-University, Frankfurt, Germany
An insertion/deletion (lD) polymorphism in the angiotensin converting en-
zyme (ACE) gene results in the genotypes II, ID, DD. The latter has been
reported to be an independent risk factor for myocardial infarction. We inves-
tigated 300 males age 20-65 scheduled for cardiac valve or bypass surgery
in a prospective cross-sectional study. After an overnight fast an oral glucose
tolerance test (GT) was performed. DNA was isolated from peripheralleuco-
cytes and ACE polymorphism was determined by polymerase chain reaction.
Coronary angiograms were assessed visually using the 15 segment AHA
Coding scheme. Coronary artery disease (CAD) was defined angiographically
with at least one stenosed segment ~50%. Extent of disease was defined
as mean of percent involvement of each segment with at least wall irregu-
larities.
CAD prevalence was similar in patients with the DD (67%). ID (66%) or II
genotype (77%).
Paul A. Friedman, Marshall S. Stanton Mayo Clinic, Rochester, MN
A recent study using a monophasic, epicardial defibrillation system in a ca-
nine model has raised COncern that congestive heart failure may dramatically
increase the energy requirements of defibrillation. In order to test the effect
of heart failure On the defibrillation efficacy of a transvenous biphasic defib-
rillation system, 16 dogs were studied; 11 dogs were ventricular paced at
225 ppm for two weeks to induce heart failure, and 5 control dogs remained
unpaced. All dogs were tested using an endocardial right ventricular defibril-
lation lead and a cutaneous patch. Shocks were biphasic with equal leading
edge voltages and fixed 65% tilt for each phase. Dose-response defibrilla-
tion probability curves were generated for each animal at baseline, after two
weeks (at which time pacing was discontinued in the paced group), and then
one week later. The ED20, ED50, and ED80 (the 20%, 50%, and 80% effective
defibrillation energies, respectively) were determined for each dog at each
study.
In the paced dogs, the ejection fraction (EF) fell from 55% to 25% after
pacing (p < 0.0001), and rose to 46% one week after its discontinuation (p
= 0.0002). The effective refractory period (ERP) prolonged from 152 to 170
msec (p < 0.005), then shortened to 164 (p = NS). There was nO significant
change in EF or ERP in the control dogs between the three studies. The
ED20 , ED50 , and ED80 remained unchanged in both the control and paced
groups for all three studies, even with adjustment for dog weight or echocar-
diographic left ventricular mass. In a multiple regression model, EF did not
significantly predict the ED50 . However, the ED50 increased with increasing
left ventricular (LV) size and decreased with LV wall thinning. Rapid pacing led
to LV cavity dilatation and wall thinning; these two morphologic changes had
We conclude that although ACE polymorphism significantly influences the
degree of ACE activity in man, it is unrelated to the prevalence, extent and
severity of CAD and to its risk factors.
'p < 0.05 DD vs II; +p < 0.05, ++p < 0.01, +++p < 0.001 CAD vs none; results are
presented as mean values
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